NASDAQ:BIOC Biocept (BIOC) Stock Price, News & Analysis → Obama’s Forever Term [exposed] (From Porter & Company) (Ad) Free BIOC Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.43▼$1.6752-Week Range N/AVolume751,400 shsAverage Volume764,067 shsMarket Capitalization$1.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Biocept alerts: Email Address Ad Porter & CompanyObama’s Forever Term [exposed]Over a decade ago, I tried to warn you... Because the same forces are once again brewing… and what’s coming next will forever reshape everything you think you know about America. Start streaming it now at no cost here About Biocept Stock (NASDAQ:BIOC)Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. On October 13, 2023, Biocept, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.Read More Ad Porter & CompanyObama’s Forever Term [exposed]Over a decade ago, I tried to warn you... Because the same forces are once again brewing… and what’s coming next will forever reshape everything you think you know about America. Start streaming it now at no cost here BIOC Stock News HeadlinesMay 8, 2024 | finanznachrichten.deLiquid Biopsy Market Worth $11.3 billion | MarketsandMarkets.May 2, 2024 | msn.comAkron residents could see water and sewer rate increases over federally mandated projectsMarch 6, 2024 | finanznachrichten.dePlus Therapeutics Inc.: Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsFebruary 27, 2024 | bizjournals.comCircular Genomics brings on 2 leadership hires following $8.3M raiseFebruary 26, 2024 | finance.yahoo.comCircular Genomics Strengthens Leadership Team with Key Commercial and Research HiresDecember 29, 2023 | fool.comBiocept (NASDAQ: BIOC)November 22, 2023 | msn.comPlus Therapeutics files to sell ordinary shares, warrantsNovember 10, 2023 | finance.yahoo.comBiocept, Inc. (BIOCQ) Stock Historical Prices & Data - Yahoo FinanceNovember 7, 2023 | benzinga.comGenomic Cancer Testing is projected to Hit $45.92 Billion, Globally, by 2030 at 16.1% CAGR: Coherent Market InsightsOctober 18, 2023 | sg.finance.yahoo.comBiocept, Inc. (BIOC) stock price, news, quote & history – Yahoo FinanceOctober 16, 2023 | marketwatch.comBiocept Falls 46% After Chapter 7 FilingOctober 16, 2023 | benzinga.comWhy Is Liquid Biopsy Firm Biocept Stock Trading Lower Today?September 22, 2023 | markets.businessinsider.comMaxim Group Remains a Hold on Biocept (BIOC)September 21, 2023 | finance.yahoo.comEnrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept’s CNSide™ Assay to Evaluate Patients with Leptomeningeal MetastasesSeptember 11, 2023 | benzinga.comThinking about buying stock in Tivic Health Systems, Axcella Health, Biocept, Aravive, or Uranium Royalty Corp?September 9, 2023 | marketwatch.comBiocept Shares Double While Plus Therapeutics Shares Sink on Licensing AgreementSeptember 8, 2023 | msn.comBiocept and Plus Therapeutics collaborate in battle against leptomeningeal metastasesSeptember 8, 2023 | finance.yahoo.comPlus Therapeutics Enters into License Agreement for Cerebrospinal Fluid Tumor Cell Enumeration AssaySeptember 5, 2023 | finance.yahoo.comBiocept to Participate in the H.C. Wainwright Global Investment ConferenceAugust 25, 2023 | businesswire.comBiocept to Hold Business Update Conference Call on August 30, 2023August 23, 2023 | thestreet.comBiocept (BIOC) Stock Popping on Blue Cross Blue Shield PartnershipAugust 17, 2023 | markets.businessinsider.comBiocept (BIOC) Gets a Hold from Maxim GroupAugust 14, 2023 | finance.yahoo.comBiocept Reports Second Quarter 2023 Financial ResultsAugust 14, 2023 | finance.yahoo.comBiocept’s CNSide™ Cerebrospinal Fluid Assay Featured in Two Oral Presentations at the 2023 SNO/ASCO CNS Cancer ConferenceAugust 1, 2023 | finance.yahoo.comBiocept, Inc. (NASDAQ:BIOC) Is Expected To Breakeven In The Near FutureSee More Headlines Receive BIOC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biocept and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolNASDAQ:BIOC CUSIPN/A CIK1044378 Webwww.biocept.com Phone(858) 320-8200Fax858-320-8225Employees50Year Founded1993Profitability EPS (Most Recent Fiscal Year)($58.4549) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,090,000.00 Net MarginsN/A Pretax Margin-564.02% Return on Equity-468.87% Return on Assets-118.41% Debt Debt-to-Equity Ratio2.88 Current Ratio1.81 Quick Ratio1.70 Sales & Book Value Annual Sales$25.86 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$15.60 per share Price / BookN/AMiscellaneous Outstanding Shares2,630,000Free Float2,584,000Market Cap$1.14 million OptionableNot Optionable Beta0.69 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Darrell Taylor Esq. (Age 58)Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Registered In-House Counsel Comp: $432.27kDr. Soon Kap Hahn Ph.D.FounderMr. Rob WalshVP & ControllerDr. Philippe J. Marchand Ph.D. (Age 60)Chief Operating Officer Mr. Pavel TsinbergDirector of Technology DevelopmentMr. David S. Moskowitz R.Ph.MBA, Vice President of Strategy & Corporate CommunicationsDr. Veena M. Singh (Age 48)Senior Medical Director Comp: $361.03kMore ExecutivesKey CompetitorsVirax Biolabs GroupNASDAQ:VRAXLucy Scientific DiscoveryNASDAQ:LSDIAcutus MedicalNASDAQ:AFIBSintx TechnologiesNASDAQ:SINT9 Meters BiopharmaNASDAQ:NMTRView All Competitors BIOC Stock Analysis - Frequently Asked Questions How were Biocept's earnings last quarter? Biocept, Inc. (NASDAQ:BIOC) released its quarterly earnings data on Monday, November, 15th. The medical research company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $2.70 by $1.80. The medical research company had revenue of $17.47 million for the quarter, compared to the consensus estimate of $16.87 million. During the same period last year, the firm posted ($12.90) EPS. When did Biocept's stock split? Biocept shares reverse split on the morning of Wednesday, May 17th 2023. The 1-30 reverse split was announced on Wednesday, May 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What is Michael Nall's approval rating as Biocept's CEO? 4 employees have rated Biocept Chief Executive Officer Michael Nall on Glassdoor.com. Michael Nall has an approval rating of 100% among the company's employees. This puts Michael Nall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at Biocept to a friend. What other stocks do shareholders of Biocept own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include T2 Biosystems (TTOO), iBio (IBIO), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Onconova Therapeutics (ONTX), Walmart (WMT), Inovio Pharmaceuticals (INO) and Acasti Pharma (ACST). This page (NASDAQ:BIOC) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account Before It’s Too LateWeiss RatingsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarWarren Buffett's "mystery stock"Stansberry ResearchThis Could be Your “Big Money” AI MomentInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biocept, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.